Holliston

Twelve out of 74 Central Massachusetts nursing homes received top care quality rankings from the Centers for Medicare & Medicaid Services.

Under the advisement of the U.S. Food & Drug Administration, Biostage has decided to extend their animal testing of its Cellframe organ implants and push back its investigational new drug (IND) filing.

Holliston-based Cold Chain Technologies today launched a new material that keeps drugs and vaccines safe while they're being transported.

Holliston's Biostage has cut its losses down even as it prepares to launch human trials of its Cellframe organ implants.

A Holliston retailer of hockey and lacrosse equipment nearly doubled its retail presence as it expands with the acquisition of a St. Louis retailer.

Over the past year, Holliston-based Biostage has revamped its upper management, changed its name and used its technology to partially recreate the esophaguses of several Yucatan pigs.

A warehouse in Holliston has sold for $7.2 million to Framingham's Atlantic Importing as the alcohol distributor prepares to move its headquarters as part of an expansion.

Holliston biotechnology firm Biostage has filed for a designation that would allow it to fast-track registrations for its Cellspan esophageal implants and gain a full exemption from the FDA's registration fees.

Biostage is moving closer to human trials of its esophagus regeneration technology, anticipated to take place in 2017, on the back of an additional $5 million in funding gained through a stock offer.

The bioengineered organ implant company Biostage has announced it will release 2.8 million shares of common stock in an effort to raise $5 million.